-
A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)Kim BK, Hong MK, RESET Investigators. -
Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trialCollet JP, Silvain J, ARCTIC investigators.
-
Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-AnalysisM Valgimigli , R Mehran, SIDNEY Collaboration et al.
-
Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS TrialSS Anand, JW Eikelboom, COMPASS Trial Investigators.
-
Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art ReviewD Capodanno, K Huber, R Mehran et al.
-
Genotyping to Guide Clopidogrel Treatment: An In-Depth Analysis of the TAILOR-PCI TrialNaveen L. Pereira, MBBS, FACC
-
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trialFeres F, Costa RA, OPTIMIZE Trial Investigators.
-
Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary InterventionD Sibbing, D Aradi, D Alexopoulos et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
